Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.
Ovarian Cancer
DRUG: Herceptin
The purpose of this study is to evaluate whether or not the addition of Herceptin may be of benefit to a standard regimen of carboplatin-paclitaxel.